| 000 | 01730 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515232040.0 | ||
| 264 | 0 | _c20110714 | |
| 008 | 201107s 0 0 eng d | ||
| 022 | _a1552-4604 | ||
| 024 | 7 |
_a10.1177/0091270010370588 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBavisotto, Linda M | |
| 245 | 0 | 0 |
_aTecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacology _cApr 2011 |
||
| 300 |
_a561-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAryl Hydrocarbon Hydroxylases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBenzoates _xadministration & dosage |
| 650 | 0 | 4 |
_aCoumarins _xadministration & dosage |
| 650 | 0 | 4 | _aCytochrome P-450 CYP2C9 |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluconazole _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNAD(P)H Dehydrogenase (Quinone) _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aEllis, David J | |
| 700 | 1 | _aMilner, Peter G | |
| 700 | 1 | _aCombs, Daniel L | |
| 700 | 1 | _aIrwin, Ian | |
| 700 | 1 | _aCanafax, Daniel M | |
| 773 | 0 |
_tJournal of clinical pharmacology _gvol. 51 _gno. 4 _gp. 561-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/0091270010370588 _zAvailable from publisher's website |
| 999 |
_c19965344 _d19965344 |
||